ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Location
Epalinges, Switzerland
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442% % -14%
Quick Ratio 27% % 9.1%
Debt-to-equity -237% % 24%
Return On Equity 76% % -42%
Return On Assets -55% % 9.7%
Operating Margin -181% % 7.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 123,877,111 shares 28%
Common Stock, Shares, Outstanding 112,626,731 shares 16%
Entity Public Float $173,400,000 USD 13%
Common Stock, Value, Issued $9,763,000 USD 19%
Weighted Average Number of Shares Outstanding, Basic 136,446,534 shares 30%
Weighted Average Number of Shares Outstanding, Diluted 136,446,534 shares 30%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $75,209,000 USD 6.4%
Revenue from Contract with Customer, Excluding Assessed Tax $15,750,000 USD -13%
Research and Development Expense $112,922,000 USD 0.05%
Selling and Marketing Expense $42,639,000 USD -8.7%
General and Administrative Expense $36,726,000 USD -16%
Costs and Expenses $211,225,000 USD 1.1%
Operating Income (Loss) $136,016,000 USD 1.6%
Nonoperating Income (Expense) $29,827,000 USD -11%
Income Tax Expense (Benefit) $1,098,000 USD -97%
Net Income (Loss) Attributable to Parent $166,941,000 USD 21%
Earnings Per Share, Basic -1 USD/shares 41%
Earnings Per Share, Diluted -1 USD/shares 41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $234,738,000 USD -14%
Inventory, Net $18,042,000 USD 12%
Other Assets, Current $5,523,000 USD
Assets, Current $287,149,000 USD -14%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $1,393,000 USD -85%
Other Assets, Noncurrent $1,216,000 USD 4.4%
Assets $289,758,000 USD -17%
Accounts Payable, Current $8,119,000 USD -44%
Accrued Liabilities, Current $53,925,000 USD 1.2%
Liabilities, Current $62,044,000 USD -8.3%
Deferred Income Tax Liabilities, Net $1,912,000 USD 44%
Operating Lease, Liability, Noncurrent $1,127,000 USD -87%
Other Liabilities, Noncurrent $9,394,000 USD 23%
Liabilities $527,941,000 USD 1.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $702,000 USD -446%
Retained Earnings (Accumulated Deficit) $1,629,532,000 USD -11%
Stockholders' Equity Attributable to Parent $238,183,000 USD -39%
Liabilities and Equity $289,758,000 USD -17%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $56,334,000 USD -28%
Net Cash Provided by (Used in) Financing Activities $271,000 USD -24%
Net Cash Provided by (Used in) Investing Activities $264,000 USD 50%
Common Stock, Shares, Issued 115,187,979 shares 16%
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $234,738,000 USD -14%
Interest Paid, Excluding Capitalized Interest, Operating Activities $3,594,000 USD -7.8%
Deferred Tax Assets, Valuation Allowance $219,836,000 USD 3.6%
Deferred Tax Assets, Gross $221,748,000 USD 3.9%
Operating Lease, Liability $2,060,000 USD
Depreciation $1,045,000 USD -21%
Payments to Acquire Property, Plant, and Equipment $264,000 USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $167,850,000 USD 21%
Lessee, Operating Lease, Liability, to be Paid $2,223,000 USD
Property, Plant and Equipment, Gross $6,335,000 USD -42%
Operating Lease, Liability, Current $933,000 USD -37%
Lessee, Operating Lease, Liability, to be Paid, Year Two $582,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $506,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $163,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $165,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $149,925,000 USD -8%
Unrecognized Tax Benefits $7,510,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Four $165,000 USD
Additional Paid in Capital $1,382,493,000 USD 7.8%
Deferred Tax Assets, Net of Valuation Allowance $1,912,000 USD 44%
Interest Expense $49,945,000 USD 2.9%